Randomized Trial Comparing Immediate Versus Deferred Surgery for Symptomatic Epiretinal Membranes

Status: Recruiting
Location: See all (45) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Vitrectomy to remove an epiretinal membrane (ERM) is one of the most common procedures performed by retinal surgeons. Patients who present with significant macular changes on optical coherence tomography (OCT) but relatively good vision are often advised to defer surgery until vision declines to 20/40 or worse. However, it is unknown if delaying surgery, which allows the foveal architecture to remain compromised and potentially to deteriorate, results in worse visual acuity outcomes than if surgery is performed earlier. In addition, there is a need to better understand predictors of outcomes when surgery is performed and predictors of progression when surgery is deferred. Finally, one of the most common presenting symptoms from an ERM is distortion or metamorphopsia. There are several objective measures of metamorphopsia but none have ever been employed to evaluate ERMs in a randomized clinical trial (RCT) and their usefulness is unknown. The purposes of this study are to better understand the optimal timing of surgery to produce the best visual result, to better understand predictors of outcomes in those who undergo surgery and predictors of progression in those whose are observed, and to better characterize and evaluate the usefulness of metamorphopsia and reading speed measures.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:

• Age ≥ 45 years

• E-ETDRS visual acuity 20/40 or better (≥69 letters)

• o ERM must be thought to be the primary cause of vision loss

• ERM meeting the following criteria, according to the investigator

‣ ERM is not secondary to another condition

⁃ Symptoms of visual loss and/or distortion (in the opinion of the investigator, the ERM is contributing to the participant's symptoms); either new or worsening in the past 24 months

⁃ Epiretinal membrane involving or altering the central 3 mm of the macula on OCT

⁃ Distortion within the central subfield due to ERM on OCT

• Immediate vitrectomy not required (investigator and participant are willing to wait at least 4 weeks to see if vision remains stable without having to proceed to vitrectomy)

• No known medical problems that will be a contraindication to surgery

Locations
United States
Arizona
Mayo Clinic Arizona
RECRUITING
Scottsdale
California
Kent W. Small, MD, AMC
RECRUITING
Glendale
Salehi Retina Institute Inc.
RECRUITING
Huntington Beach
Loma Linda University
RECRUITING
Loma Linda
Retina Vitreous Associates, Northern California Retina Vitreous Assoc Medical Group, Inc.
RECRUITING
Mountain View
East Bay Retina Consultants, Inc.
RECRUITING
Oakland
Regents of the University of California, Davis, DBA University of California, Davis
RECRUITING
Sacramento
Macula Retina Vitreous Institute
RECRUITING
Torrance
Florida
Florida Retina Institute, James A. Staman, MD, PA- Jacksonville
RECRUITING
Jacksonville
Sarasota Retina Institute
RECRUITING
Sarasota
SEASHORE RETINA LLC DBA Retina Specialists of Tampa
RECRUITING
Wesley Chapel
Georgia
Southeast Retina Center, P.C.
RECRUITING
Augusta
Thomas Eye Group
RECRUITING
Sandy Springs
Illinois
Northwestern University
RECRUITING
Chicago
Rush University Medical Center
RECRUITING
Chicago
Illinois Retina Associates SC - Oak Park Site
RECRUITING
Oak Park
Indiana
Raj K. Maturi, M.D., P.C.
RECRUITING
Indianapolis
Kansas
Mid-America Retina Consultants, P.A.
RECRUITING
Overland Park
University of Kansas Medical Center Research Institute, Inc.
RECRUITING
Prairie Village
Louisiana
Joseph E. Humble and Raymond Haik PTRS DBA Eye Assoc of Northeast Louisiana
RECRUITING
West Monroe
Massachusetts
Valley Eye Physicians and Surgeons
RECRUITING
Ayer
Joslin Diabetes Center
RECRUITING
Boston
Maryland
Elman Retina Group, P.A.
RECRUITING
Baltimore
Johns Hopkins University
RECRUITING
Baltimore
Michigan
Retina Associates of Michigan
RECRUITING
Grand Blanc
Missouri
The Curators of the University of Missouri
RECRUITING
Columbia
Retina Research Institute, LLC
RECRUITING
St Louis
North Carolina
University of North Carolina at Chapel Hill
RECRUITING
Chapel Hill
New York
Retina-Vitreous Surgeons of Central NY, PC
RECRUITING
Liverpool
Retina Associates of Western NY, P.C.
RECRUITING
Rochester
Oklahoma
Retina Vitreous Center
RECRUITING
Edmond
Oregon
Verum Research LLC
RECRUITING
Eugene
Cascade Medical Research Institute, LLC
RECRUITING
Springfield
Pennsylvania
Retina-Vitreous Consultants, Inc.
RECRUITING
Monroeville
The Trustees of the University of Pennsylvania
RECRUITING
Philadelphia
Pittsburg Clinical Trial Consortium
RECRUITING
Sewickley
South Carolina
Hilton Head Retina Institute
RECRUITING
Hilton Head Island
South Dakota
Ophthalmology Ltd.
RECRUITING
Sioux Falls
Tennessee
Vanderbilt Eye Institute
RECRUITING
Nashville
Texas
Austin Research Center for Retina
RECRUITING
Austin
Retina Consultants of Texas
RECRUITING
Bellaire
Baylor College of Medicine, Baylor Eye Physicians and Surgeons
RECRUITING
Houston
Texas Retina Associates
RECRUITING
Lubbock
Retinal Consultants of San Antonio
RECRUITING
San Antonio
Washington
Spokane Eye Clinical Research, PLLC
RECRUITING
Spokane
Time Frame
Start Date: 2022-02-22
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 400
Treatments
Active_comparator: Immediate Vitrectomy
Other: Deferred Vitrectomy
Related Therapeutic Areas
Sponsors
Collaborators: Juvenile Diabetes Research Foundation, National Institutes of Health (NIH), National Eye Institute (NEI)
Leads: Jaeb Center for Health Research

This content was sourced from clinicaltrials.gov